Eyeing its post-Humira future, AbbVie angles for broader Rinvoq use in U.S., Europenews2022-01-10T13:42:20+00:00January 10th, 2022|Fierce Pharma|
Idorsia scores FDA go-ahead for insomnia drug Quviviq to rival Merck’s Belsomra, Eisai’s Dayvigonews2022-01-10T13:09:09+00:00January 10th, 2022|Fierce Pharma|
#JPM22, Day 1: Bristol Myers Squibb’s blockbuster losses of exclusivity, Novartis’ spending plans and morenews2022-01-10T12:30:36+00:00January 10th, 2022|Fierce Pharma|
UPDATED: JPM22, Day 1: Merck’s COVID antiviral, Novartis’ spending plans, Pfizer’s COVID production and morenews2022-01-10T12:30:36+00:00January 10th, 2022|Fierce Pharma|
Red often means stop in new glaucoma survey from Bausch + Lombnews2022-01-10T12:16:47+00:00January 10th, 2022|Fierce Pharma|
How can pharma engage with caregivers? Try programs that ease their stressnews2022-01-10T00:20:51+00:00January 10th, 2022|Fierce Pharma|
The drive to digital in pharma marketing is ‘overwhelming’ doctors. Solution? Train digitally savvy repsnews2022-01-08T17:50:52+00:00January 8th, 2022|Fierce Pharma|
Catalent FDA write-up ‘allegedly’ the culprit behind Novo Nordisk’s Wegovy supply woes: reportnews2022-01-07T21:27:23+00:00January 7th, 2022|Fierce Pharma|
Catalent’s FDA write-up spurred Novo Nordisk’s Wegovy supply woesnews2022-01-07T21:27:23+00:00January 7th, 2022|Fierce Pharma|
CEO pay for Pfizer, J&J, Moderna and AstraZeneca should be tied to COVID-19 vaccine equity, investors saynews2022-01-07T16:05:57+00:00January 7th, 2022|Fierce Pharma|
